| Year |
Citation |
Score |
| 2020 |
Lim CJ, Nguyen PHD, Wasser M, Kumar P, Lee YH, Nasir NJM, Chua C, Lai L, Hazirah SN, Loh JJH, Khor LY, Yeong J, Lim TKH, Low AWX, Albani S, ... Chong TW, et al. Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer. Frontiers in Immunology. 11: 615091. PMID 33584702 DOI: 10.3389/fimmu.2020.615091 |
0.314 |
|
| 2012 |
Yuen JS, Sim MY, Sim HG, Chong TW, Lau WK, Cheng CW, Ong RW, Huynh H. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma. International Journal of Oncology. 41: 712-20. PMID 22641227 DOI: 10.3892/ijo.2012.1494 |
0.354 |
|
| 2004 |
Silk JD, Hermans IF, Gileadi U, Chong TW, Shepherd D, Salio M, Mathew B, Schmidt RR, Lunt SJ, Williams KJ, Stratford IJ, Harris AL, Cerundolo V. Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell-mediated immunotherapy. The Journal of Clinical Investigation. 114: 1800-11. PMID 15599405 DOI: 10.1172/Jci200422046 |
0.498 |
|
| 2003 |
Hermans IF, Chong TW, Palmowski MJ, Harris AL, Cerundolo V. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Research. 63: 8408-13. PMID 14679003 |
0.494 |
|
| 2002 |
Chong TW, Horwitz LD, Moore JW, Sowter HM, Harris AL. A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines. Cancer Research. 62: 6924-7. PMID 12460908 |
0.412 |
|
| Show low-probability matches. |